NextCure Inc
NASDAQ:NXTC
Intrinsic Value
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. [ Read More ]
The intrinsic value of one NXTC stock under the Base Case scenario is 3.88 USD. Compared to the current market price of 1.6 USD, NextCure Inc is Undervalued by 59%.
Valuation Backtest
NextCure Inc
Run backtest to discover the historical profit from buying and selling NXTC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
NextCure Inc
Current Assets | 112.7m |
Cash & Short-Term Investments | 108.3m |
Other Current Assets | 4.4m |
Non-Current Assets | 15.3m |
PP&E | 13.4m |
Other Non-Current Assets | 1.9m |
Current Liabilities | 6.9m |
Accounts Payable | 2.3m |
Accrued Liabilities | 4.6m |
Non-Current Liabilities | 6.7m |
Other Non-Current Liabilities | 6.7m |
Earnings Waterfall
NextCure Inc
Revenue
|
0
USD
|
Operating Expenses
|
-67.6m
USD
|
Operating Income
|
-67.6m
USD
|
Other Expenses
|
4.9m
USD
|
Net Income
|
-62.7m
USD
|
Free Cash Flow Analysis
NextCure Inc
What is Free Cash Flow?
NXTC Profitability Score
Profitability Due Diligence
NextCure Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
NextCure Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
NXTC Solvency Score
Solvency Due Diligence
NextCure Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
NextCure Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NXTC Price Targets Summary
NextCure Inc
According to Wall Street analysts, the average 1-year price target for NXTC is 5.1 USD with a low forecast of 3.03 USD and a high forecast of 8.4 USD.
Ownership
NXTC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NXTC Price
NextCure Inc
Average Annual Return | -4.86% |
Standard Deviation of Annual Returns | 124.26% |
Max Drawdown | -99% |
Market Capitalization | 44.6m USD |
Shares Outstanding | 27 903 000 |
Percentage of Shares Shorted | 3.63% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 86 full-time employees. The company went IPO on 2019-05-09. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO), platform, the Company is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC318, NC410, NC762 and NC 525. NC318, is an immunomedicine against a novel immunomodulatory protein called Siglec-15. NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor. NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein. NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia.
Contact
IPO
Employees
Officers
The intrinsic value of one NXTC stock under the Base Case scenario is 3.88 USD.
Compared to the current market price of 1.6 USD, NextCure Inc is Undervalued by 59%.